logo
Scientists Finally Identified Where Gluten Reactions Start

Scientists Finally Identified Where Gluten Reactions Start

Yahoo23-03-2025

For roughly one in every hundred people, food containing even the smallest amounts of gluten can deliver a gutful of hurt and pose severe risks to their health.
While a domino effect of immunological reactions can be traced back to their genetic roots, a number of contributing factors are also involved, making it difficult to map the precise chain of events that causes celiac disease.
Using transgenic mice, an international team led by scientists from McMaster University in Canada has identified a crucial role played by the very cells making up the gut's lining, describing a major stepping stone that could lead to new therapies.
Celiac disease is a lifelong autoimmune disorder triggered by the presence of a group of structural proteins known as gluten in the intestines.
Eating virtually anything made with wheat, barley, or rye – meaning most baked goods, breads, and pastas – puts people with the condition at risk of transient symptoms like bloating, pain, diarrhea, constipation, and sometimes reflux and vomiting.
Currently the only way to avoid the symptoms is to avoid the foods that trigger them. Over the longer term, immune attacks triggered by gluten can damage the small intestine's villi. These tiny structures increase the internal surface area of the intestinal walls, which aids absorption of nutrients from food.
People with celiac disease – particularly if it's untreated – face serious health risks, such as being more likely to develop colorectal cancer and cardiovascular disease. The disease is associated with a myriad of conditions, with just some examples including anemia, osteoporosis, growth delays, reproductive issues, and neurological disorders.
"The only way we can treat celiac disease today is by fully eliminating gluten from the diet," says McMasters gastroenterologist Elena Verdu.
"This is difficult to do, and experts agree that a gluten-free diet is insufficient."
Around 90 percent of people diagnosed with the condition carry a pair of genes that encode for a protein called HLA-DQ2.5. Of the remaining 10 percent, most have a similar protein called HLA-DQ8.
Like other kinds of 'HLA' (or human leukocyte antigen) proteins, the proteins hold pieces of fallen invaders aloft like macabre trophies on a class of immune cells, warning other defensive tissues to be on the lookout.
In the specific case of HLA-DQ2.5 and HLA-DQ8, the proteins are shaped to hold chunks of gluten peptide that are resistant to digestion, instructing murderous T cells to go on the hunt.
Unfortunately, these instructions aren't the clearest at distinguishing between a threat and similar-looking materials in our body, meaning those with the genes are at risk of a variety of autoimmune conditions.
Not everybody who expresses either HLA-DQ2.5 or HLA-DQ8 will develop an immune disorder like celiac disease, however.
For that to happen, those torn-up pieces of gluten first need to be carried across the gut wall by a transporting enzyme that binds with the peptide and alters it in ways to make it even more recognizable.
Cells in the intestinal wall are responsible for releasing this transporting enzyme into the gut, so they clearly have a critical role in the early stages of the disease.
They are also known to express the family of proteins to which HLA-DQ2.5 and HLA-DQ8 belong, which are typically regulated by inflammatory responses in the gut.
What hasn't been clear is how this staging ground for people with celiac disease actually functions within the pathology itself.
To focus on this important link in the chain, the research team double-checked the expression of the major immune complex in the cells lining the intestines of people with treated and untreated celiac disease, and in mice with the human genes for HLA-DQ2.5.
They then created functional living models of the gut, called an organoid, using the mouse intestinal cells, to study the expression of their immune proteins up close, subjecting them to inflammatory triggers as well as predigested and intact gluten.
"This allowed us to narrow down the specific cause and effect and prove exactly whether and how the reaction takes place," says McMasters biomedical engineer Tohid Didar.
From this it became evident the cells lining the gut weren't just passive bystanders suffering collateral damage in a misguided effort to rid the body of gluten – they were key agents, presenting a mash-up of gluten fragments broken down by gut bacteria and transporting enzymes to gluten-specific immune cells firsthand.
Knowing the types of tissue involved and their enhancement by the presence of inflammatory microbes gives researchers a new list of targets for future treatments, potentially allowing millions of people worldwide to enjoy a gluten-filled pastry or two without the risk of discomfort.
This research was published in Gastroenterology.
An earlier version of this article was published in August 2024.
How Often You Should Wash Your Exercise Clothes, According to Science
High-Protein And Fiber Diet Linked to Longer, Better Sleep, Study Finds
Lifespan Is Shaped More By Your Choices Than Your Genes, Study Finds

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

This Genetic ‘Trick' Helped the Black Death Linger for Centuries
This Genetic ‘Trick' Helped the Black Death Linger for Centuries

Gizmodo

time4 hours ago

  • Gizmodo

This Genetic ‘Trick' Helped the Black Death Linger for Centuries

Yersinia pestis—the bacterium that causes the bubonic plague—experienced a genetic tweak that allowed rodents to live longer after they were infected, according to a new study. This alteration may have prolonged two significant plague pandemics, including the deadliest event in human history: the Black Death. Researchers at the Institut Pasteur in France and McMaster University in Canada studied hundreds of ancient Y. pestis DNA samples to investigate a gene called 'pla.' Their study, published May 29 in the journal Science, identified a decrease in repetitions of the pla gene in the Y. pestis genome during the later stages of both the first and second major plague pandemics. The researchers believe these pla depletions ultimately allowed these pandemics to last longer. The first plague pandemic, known as the Plague of Justinian, struck the Mediterranean basin during the sixth century and caused tens of millions of deaths over the course of two centuries. The second emerged when the Black Death broke out in 1347, killing an estimated 30% to 50% of Europe's population in just six years. But this was just the beginning. Like the first pandemic, this plague continued to reemerge for centuries, lasting more than 500 years. This newly discovered evolution of the pla gene offers more insight into how these plagues persisted for so long. The pla gene appears many times in the Y. pestis' genome and plays a crucial role in its virulence by allowing it to infect the lymph nodes before traveling to the rest of the body, according to an Institut Pasteur statement. This causes rapid septicemia—or blood poisoning—and quickly kills the victim. Therefore, a lack of this gene in Y. pestis strains from the first and second major pandemics likely made the bacterium less virulent, the researchers suggest. To test that hypothesis, they infected mice with three preserved strains of Y. pestis from the third major pandemic that also had fewer repetitions of pla. 'These three samples enabled us to analyze the biological impact of these pla gene deletions,' said co-author Javier Pizarro-Cerdá, director of the Yersinia Research Unit at the Institut Pasteur, according to the statement. Through their mouse model, Pizarro-Cerdá and his colleagues found that the pla depletion resulted in a 20% decrease in victim mortality. What's more, it allowed infected rodents to live significantly longer. Based on these findings, the researchers concluded that rats infected with pla-depleted Y. pestis strains may have been more effective disease vectors, as they had more time to spread the plague far and wide before they died. Rodents—particularly rats—played a critical role in spreading the bubonic plague to humans. People most commonly contract this disease via infected flea bites, and fleas typically contract it when they feed on infected rodents. Thus, an increase in the lifespans of sickened rodents would have provided greater opportunity for fleas to bite them, become infected, and then bite humans. 'Ours is one of the first research studies to directly examine changes in an ancient pathogen, one we still see today, in an attempt to understand what drives the virulence, persistence, and eventual extinction of pandemics,' said co-lead author Hendrik Poinar, director of the McMaster Ancient DNA Centre and holder of the Michael G. DeGroote Chair in Genetic Anthropology, according to the statement. Today, the bubonic plague is considered a rare disease, though a small number of cases still emerge in western North America, Africa, Asia, and South America, according to the Cleveland Clinic. While this research provides valuable insight into the evolutionary history of Y. pestis and the world-altering pandemics it caused, it can also serve as a model for better understanding how deadly diseases emerge and spread, according to the researchers.

How Much Does Maintaining BP During Surgery Matter?
How Much Does Maintaining BP During Surgery Matter?

Medscape

time12 hours ago

  • Medscape

How Much Does Maintaining BP During Surgery Matter?

Efforts to avoid either high or low blood pressure during noncardiac surgery do not appear to make a difference in the cognitive outcomes of patients after the procedures, a new study found. More than 300 million adults worldwide undergo noncardiac surgery each year, and most are taking medications to control their blood pressure, said Maura Marcucci, MD, a specialist in perioperative medicine at McMaster University in Hamilton, Ontario, Canada, and lead author of the study, which her group published last month in Annals of Internal Medicine . 'Blood pressure abnormalities are common during and after noncardiac surgery, and observational evidence have suggested that they are related to possible organ damage, including brain insult, especially in older patients and those whose mechanisms of brain protection might be affected by chronic vascular disease,' Marcucci said. 'On a daily basis, physicians taking care of these patients are confronted with questions around what blood pressure to target intraoperatively and what to do with the patient's blood pressure medications, with the assumption that these choices would affect the patient's risk of complications.' The new study evaluated 2603 surgery patients (mean age, 70 years) with a history of vascular disease or multiple risk factors for vascular events and who were taking antihypertensive medications chronically. The researchers compared outcomes associated with two approaches to regulating blood pressure during the procedures: One aimed to prevent hypotension, the other to avoid hypertension. The primary outcome was delirium in the hospital in the first 3 days after surgery. In the hypotension-avoidance group, patients taking angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or direct renin inhibitors have those medications withheld before surgery and for the first 2 days afterward. For other types of blood pressure medications, decisions on whether to continue or discontinue the drugs were based on the patient's systolic blood pressure following surgery (≥ 130 mm Hg following an algorithm). Anesthesiologists were asked to maintain patients' mean arterial pressure (MAP) ≥ 80 mm Hg throughout surgery. In the hypertension-avoidance group, patients took all of their usual blood pressure medications at the hospital before their operation. The anesthesiologists in these cases were asked to aim to keep MAPs ≥ 60 mm Hg throughout surgery using strategies at their discretion. After surgery, the patients in this group continued taking all of their blood pressure medications as they normally would. All the patients remained on their assigned blood pressure management strategy for 2 days after surgery or until they were discharged from the hospital, whichever came first. In the hypotension-avoidance group, on day 3 after surgery or at discharge, patients were allowed to resume taking all of their blood pressure medications. Marcucci and her colleagues found no difference in neurocognitive outcomes between the two strategies in either the short or the long term. The analysis showed 95 of 1310 patients (7.3%) in the hypotension-avoidance group and 90 of 1293 patients (7%) in the hypertension-avoidance group had delirium (relative risk [RR], 1.04; 95% CI, 0.79-1.38). Of the 701 patients who completed the cognitive assessment at the 1-year mark, 129 of 347 (37.2%) in the hypotension-avoidance group and 117 of 354 (33.1%) in the hypertension-avoidance group had a decline of two or more points on the test (RR, 1.13; 95% CI, 0.92-1.38). By the end of the trial, 19% in the hypotension-avoidance strategy and 27% in the hypertension-avoidance strategy had hypotension requiring some form of intervention (RR, 0.63; 95% CI, 0.52-0.76). Marcucci said the study helps answer two important questions confronting anesthesiologists, cardiologists, and internists: 'It taught us that ensuring that patients' MAP remains above 60 throughout the surgery is safe and that targeting a higher MAP does not make a difference,' she said. 'Also, whether or not patients continued to take all their chronic blood pressure medications throughout the perioperative period did not make any real difference to their blood pressure and heart rate, and hence any difference in patient-centered outcomes.' That the findings held across different subgroups of patients — from young to old, and those on single or multiple drugs for hypertension — 'are reassuring regarding the fact that patients are stable on their chronic medications and that it does not seem that their continuation or discontinuation perioperatively will affect major outcomes, at least not on average. They also leave discretion to physicians to individualize care based on specific situations and following patients' preferences.' In an editorial accompanying the journal article, Idalid Franco, MD, MPH, and Alexander Arriaga, MD, MPH, ScD, of Brigham and Women's Hospital in Boston, wrote the study 'adds to a growing list of publications from high-impact journals, including Annals of Internal Medicine , that have used original research and multidisciplinary guidelines to challenge and update long-standing beliefs about the perioperative management of older adults' and renin-angiotensin-aldosterone system inhibitors (RAASIs). 'At a time when substantial resources are being devoted to improving the quality of perioperative care for an increasingly aging population, Marcucci and colleagues provide us timely and relevant reassurance that the key to improving outcomes may not rely on whether a few doses of RAASIs are held perioperatively or whether intraoperative MAP targets are scripted beyond clinical judgment,' they added.

Hamilton allergy season primed to take off as warm and dry weather approaches
Hamilton allergy season primed to take off as warm and dry weather approaches

Hamilton Spectator

time2 days ago

  • Hamilton Spectator

Hamilton allergy season primed to take off as warm and dry weather approaches

After a slightly delayed start, Hamilton's allergy season is now well underway. 'There's a direct correlation between pollen counts and weather. Pollen loves warm weather,' said Daniel Coates of Aerobiology Research Laboratories, the country's leading pollen monitoring lab. A harsh and snowy winter spelled a later — but still early by historical standards — launch for this year's allergy season, with pollen first recorded in Hamilton on March 11 compared to Feb. 28 in 2024, according to data provided by the Ottawa-based lab. Cooler temperatures in early April and parts of May stalled the season's momentum, creating what Coates likened to a bottleneck effect. He said cold snaps cause pollen to either stop releasing or to release at very low levels. But when the weather suddenly warms — like it did in mid-April — 'we see an explosion of pollen,' Coates said. 'It starts to release over a shorter period of time but at heightened levels.' Among the top culprits this spring are birch, alder, oak, walnut and butternut trees. 'And pine, that yellow dust you see on your car or patio furniture? It's really taking off,' Coates said. 'In the last few weeks, it's been rising to moderate levels, but it's about to hit high and very high levels.' Despite the late start, Hamilton has recorded 33,001 grains of pollen per cubic metre so far this year, compared to the 26,330 grains per cubic metre received over the same period in 2024, according to Coates. And while day-to-day pollen levels fluctuate, Coates said the longer-term trends are clear: Hamilton is getting more pollen, and more of it landing earlier. The same can be said for Canada as a whole. 'Back in 2020, we saw just under 500,000 grains of pollen per cubic metres across Canada. In 2024, it was up close to one million,' Coates said. 'Pollen is like a business; it goes up and down. But if you look at the trend line over the last five years, it's only going one way.' 'As we get into the warmer spring and summer months, it promises to be an active pollen season with high counts,' added Dr. Mariam Hanna, an allergy and asthma specialist at McMaster University who also runs a pediatric clinic in Burlington. Hanna said her clinic still saw patients coming in with bad allergies despite the cool start spring. People should anticipate stronger allergy symptoms as the weather becomes dryer and warmer, she added — especially those who've already experienced them. 'If you were having allergy problems earlier, you might notice it a lot more now as we get into warm days with wind blowing around all the pollen.' Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store